Table 2.
Clinical characteristics of inflammatory bowel disease patients at time of inclusion n (%)
| CD | UC | ||
| (n = 271) | (n = 187) | ||
| Male/female (n) | 115/156 | 86/101 | |
| Age (yr)1 | 31 (24.0-41.0) | 40 (29.0-52.0) | |
| Age at presentation (yr)1 | 25 (19.0-33.0) | 33 (23.0-43.0) | |
| Duration (yr)1 | 4 (1.0-9.0) | 4 (1.0-11.0) | |
| Familial IBD | 12 (4.4) | 6 (3.2) | |
| Location | |||
| L1 | 46 (17.0) | Proctitis | 30 (16.0) |
| L2 | 67 (24.7) | Left-sided | 104 (55.6) |
| L3 | 157 (57.9) | Extensive | 53 (28.3) |
| L4 only | 1 (0.4) | ||
| All L4 | 18 | ||
| Behavior | |||
| B1 | 154 (56.5) | Remitting | 174 (93.0) |
| B2 | 56 (20.7) | Continuous | 12 (6.4) |
| B3 | 61 (22.5) | Prolonged remission | 1 (0.5) |
| Perianal disease | 76 (27.5) | - | |
| Arthritis | 54 (19.9) | 26 (13.9) | |
| Ocular manifestations | 65 (24.0) | 12 (6.4) | |
| Cutaneous manifestation | 35 (12.9) | 16 (8.6) | |
| PSC | 9 (3.3) | 8 (4.3) | |
| Steroid use/refractory | 242 (89.3)/32 (13.2) | 144 (77.0)/11 (7.6) | |
| Azathioprine use | 196 (72.3) | 66 (35.3) | |
| Surgery/multiple in CD | 54 (19.6)/19 (7.0) | 7 (3.7) | |
| Biological use | 106 (39.1) | 25 (13.4) | |
| Smoking habits | |||
| never | 219 (80.8) | 167 (89.3) | |
| yes | 47 (17.3) | 18 (9.6) | |
| previous | 5 (1.8) | 2 (1.1) | |
| Disease activity | |||
| Inactive HBI ≤ 4 | 199 (73.4) | Inactive partial Mayo ≤ 3 | 135 (72.2) |
| Active partial Mayo > 4 | |||
| Active HBI ≥ 5 | 72 (26.6) | 52 (27.8) |
1
Median (IQR). Location: L1: Ileal; L2: Colonic; L3: Ileocolonic; L4: Upper gastrointestinal disease; Behavior: B1: Inflammatory; B2: Stenosing; B3: Penetrating; PSC: Primary sclerosing cholangitis; Surgery: CD-related abdominal surgery and colectomy in UC; HBI: Harvey-Bradshaw Index; CD: Crohn’s disease; UC: Ulcerative colitis.